Boehringer touts Pradaxa antidote data as FDA decision nears

Carly Helfand LONDON–Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker ...

J&J touts a blockbuster-rich pipeline with 10 filings on the horizon

Damian Garde Johnson & Johnson says it's on track to submit more than 10 new drugs for FDA approval over the next four years, and the company believes each of those contenders ...

Shire touts R&D benefits in defense of tax model

Nick Paul Taylor Shire CEO Flemming Ornskov has come out fighting against vocal critics of the company's tax model. As Ornskov sees it, Shire's tax structure is fully legal, ...

Valeant CEO touts R&D output with new dermatology approval

Carly Helfand Less than two weeks after losing longtime acquisition target Allergan–which happily sold itself to Actavis to dodge Valeant's hostile bid and the R&D cuts ...

Keryx touts its kidney drug with an FDA decision around the corner

Damian Garde Keryx Biopharmaceuticals' in-development Zerenex helped reduce dangerous buildups of phosphorus in patients on kidney dialysis, meeting its goals in a Phase III study ...

AbbVie chief quietly touts his Shire deal to shareholders, signaling a new bid

Carly Helfand After three failed bids for Ireland's Shire, AbbVie CEO Richard Gonzalez may be considering upping his bid. But first, he's making his case to major to Shire shareholders, ...

AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline

Damian Garde Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off ...

Valeant touts quick cost cuts in $45B hostile bid for Allergan

Carly Helfand As The Wall Street Journal reports, the Irvine, CA-based Allergan is the latest apple of deal-happy Valeant's eye. And allied with activist investor Bill Ackman–who ...

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their ...

MannKind touts good news from Afrezza inhaled insulin trial

Tracy Staton MannKind says it has gathered clearly positive late-stage data on its inhaled insulin Afrezza from a pair of Phase III studies on Type 1 and Type 2 diabetes. FiercePharma ...

FDA’s Hamburg touts rising approval record and promises swifter interaction

John Carroll Margaret Hamburg, the head of the FDA, turned up at Reuters Health Summit with a bullish assessment of both the agency's responsiveness as well as the biopharma industry's ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS